SUMMIT THERAPEUTICS INC
SMMTNASDAQTrading Snapshot
- Day Range
- $14.89 – $15.31
- 52-Week Range
- $12.25 – $30.05
- Volume
- $1.75B
- Avg Volume
- $1.50B
- Shares Outstanding
- 797.8M
- Next Earnings
- Oct 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $960,000
- Last Q Revenue
- $231,892
- P/E Ratio
- —
- P/S Ratio
- 12356.8x
- EPS (TTM)
- $-1.12
- Dividend Yield
- —
Why Investors Own SMMT
- ✓High-growth profile — revenue up +41.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 67% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About SUMMIT THERAPEUTICS INC
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Summit Therapeutics Expands Its Clinical Development Program For Ivonescimab Into Urothelial Carcinoma An Orbladder Cancer, With The Initiation Of The Global, Multi-Regional Phase II/III HARMONi-GU1 Trial
HARMONi-GU1 Is First Global Registrational Clinical Trial of Ivonescimab in a Genitourinary (GU) Cancer, Adding to Global Phase III Ivonescimab Studies in NSCLC and CRCClinical Trial Site Activations Globally Planned to
Jim Cramer Calls Summit Therapeutics A 'Great Spec,' Recommends Buying This Consumer Cyclical Stock
"Mad Money" host Jim Cramer recommends buying Carvana and Summit Therapeutics. Reddit "surprised" him. Here's why.
Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches
Summit Therapeutics is upgraded to Hold as the FDA reviews its BLA for ivonescimab; a decision is expected by November 14, 2026. Read more on SMMT stock here.
Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line Expansions
Initiate Arcus Biosciences with a Buy rating: casdatifan phase 3 ccRCC catalysts, 1L upside, and $876M cash runway to 2H 2028. Click to read my analysis.
Alpha Buying: When a CEO Spends $5 Million on His Own Stock, Pay Attention
Corporate executives say optimistic things about their companies every day. They appear on earnings calls, investor presentations and financial television programs to explain why the latest disappointing quarter is
Summit Therapeutics Flags Going Concern Risk Over Cash Needs
Summit Therapeutics beat second-quarter estimates but warned current cash is insufficient to fund operations for the next year.